Back to top

Tale of the Tape

Zacks Equity Research

Cell Therapeutics Inc. (CTIC) Shares March Higher, Can It Continue?
January 07, 2014

Trades from $3
Investors certainly have to be happy with Cell Therapeutics Inc. (CTIC) and its short term performance. After all, the stock has jumped by 15.2% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for CTIC?

While we can never know for sure, it is pretty encouraging that estimates for CTIC have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #2 (Buy), so the recent move higher for this spotlighted company may definitely continue over the next few weeks.